Successful Treatment of a Patient with Anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab Plus Denosumab Combination Therapy

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2020 Apr 21

PMID 32308589

Citations 4

Authors

Taku Fujimura

Yumi Kambayashi

Kentaro Ohuchi

Ryo Amagai

Yota Sato

Kayo Tanita

Akira Hashimoto

Setsuya Aiba

Affiliations

Soon will be listed here.

Abstract

Since the incidence of mucosal melanoma is higher in the Japanese population compared to Caucasians, and since mucosal melanoma possesses a lower mutation burden compared to cutaneous melanoma, the efficacy of anti-PD1 antibody (Ab) monotherapy for mucosal melanoma is limited. Therefore, other targeting molecules that enhance the anti-tumor effects of immune checkpoint inhibitors are needed. In this report, we present a case with anti-PD1 Ab-resistant recurrent malignant melanoma of the nasal cavity successfully treated with nivolu-mab, ipilimumab plus denosumab combination therapy.

Citing Articles

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases.

Mabrut E, Mainbourg S, Peron J, Maillet D, Dalle S, Fontaine Delaruelle C J Bone Oncol. 2024; 48:100634.

PMID: 39381634 PMC: 11460504. DOI: 10.1016/j.jbo.2024.100634.

Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman.

Khatri S, Kashfi S, Griffin S Cureus. 2023; 15(5):e38581.

PMID: 37284406 PMC: 10239609. DOI: 10.7759/cureus.38581.

Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study.

Scherzad A, Stoth M, Meyer T, Haug L, Gehrke T, Schilling B Eur Arch Otorhinolaryngol. 2023; 280(9):4215-4223.

PMID: 37272953 PMC: 10382337. DOI: 10.1007/s00405-023-08015-8.

RAGE Signaling in Melanoma Tumors.

Olaoba O, Kadasah S, Vetter S, Leclerc E Int J Mol Sci. 2020; 21(23).

PMID: 33256110 PMC: 7730603. DOI: 10.3390/ijms21238989.

References

Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T . Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. J Dermatol Sci. 2017; 89(1):60-66. DOI: 10.1016/j.jdermsci.2017.10.009. View

van Dam P, Verhoeven Y, Trinh X, Wouters A, Lardon F, Prenen H . RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2019; 133:85-91. DOI: 10.1016/j.critrevonc.2018.10.011. View

Smyth M, Yagita H, McArthur G . Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. J Clin Oncol. 2014; 34(12):e104-6. DOI: 10.1200/JCO.2013.51.3572. View

Yoshida S, Fujimura T, Kambayashi Y, Amagai R, Hashimoto A, Aiba S . Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy. Case Rep Oncol. 2019; 12(3):829-833. PMC: 6872996. DOI: 10.1159/000504019. View

Ahern E, Harjunpaa H, ODonnell J, Allen S, Dougall W, Teng M . RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. Oncoimmunology. 2018; 7(6):e1431088. PMC: 5980384. DOI: 10.1080/2162402X.2018.1431088. View

Fujimura T, Okuyama R, Ohtani T, Ito Y, Haga T, Hashimoto A . Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol. 2009; 34(7):793-9. DOI: 10.1111/j.1365-2230.2009.03207.x. View

Kakizaki A, Fujimura T, Furudate S, Kambayashi Y, Yamauchi T, Yagita H . Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. Oncoimmunology. 2015; 4(11):e1047584. PMC: 4589056. DOI: 10.1080/2162402X.2015.1047584. View

Fujimura T, Kambayashi Y, Sato Y, Tanita K, Tono H, Lyu C . Successful treatment of unresectable recurrent programmed death ligand 1 moderately-expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy. J Dermatol. 2019; 46(7):e260. DOI: 10.1111/1346-8138.14786. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

10.

Ahern E, Harjunpaa H, Barkauskas D, Allen S, Takeda K, Yagita H . Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clin Cancer Res. 2017; 23(19):5789-5801. DOI: 10.1158/1078-0432.CCR-17-0606. View

11.

Weber J, Gibney G, Sullivan R, Sosman J, Slingluff Jr C, Lawrence D . Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016; 17(7):943-955. PMC: 5474305. DOI: 10.1016/S1470-2045(16)30126-7. View

12.

Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H . Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med. 2019; 8(5):2146-2156. PMC: 6536943. DOI: 10.1002/cam4.2110. View

13.

Saijo K, Imai H, Ouchi K, Okada Y, Sato Y, Komine K . Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study. Tohoku J Exp Med. 2019; 248(1):37-43. DOI: 10.1620/tjem.248.37. View

14.

Hayward N, Wilmott J, Waddell N, Johansson P, Field M, Nones K . Whole-genome landscapes of major melanoma subtypes. Nature. 2017; 545(7653):175-180. DOI: 10.1038/nature22071. View

15.

DAngelo S, Larkin J, Sosman J, Lebbe C, Brady B, Neyns B . Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol. 2017; 35(2):226-235. PMC: 5559888. DOI: 10.1200/JCO.2016.67.9258. View

16.

Carlino M, Long G, Schadendorf D, Robert C, Ribas A, Richtig E . Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018; 101:236-243. DOI: 10.1016/j.ejca.2018.06.034. View

17.

Hamid O, Robert C, Ribas A, Hodi F, Walpole E, Daud A . Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018; 119(6):670-674. PMC: 6173747. DOI: 10.1038/s41416-018-0207-6. View